Press release on financial results Q2&H1FY27

October 26, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Press Release – Q2 & H1 FY27 Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Please find enclosed herewith the Press Release on Financial Results of the Company for the Q2 & H1 FY27. The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com. You are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A/a Press Release Strong Revenue growth of 17%; EBITDA up by 27% and PAT up by 38%; Domestic Business¹ delivered robust growth of 16% New Delhi, India, 26th October, 2026: Mankind Pharma (BSE: 543904 | NSE: MANKIND) India’s fourth largest pharmaceutical Company today announced its financial results for the second quarter and half year ended 30th September 2026. The information mentioned in this release is based on consolidated financial statements. Revenues Dom. Revenue1 EBITDA INR 4,338 Crore INR 3,428 Crore INR 1,175 Crore Q2 FY27 17% YoY 16% YoY 27% YoY Revenues Dom. Revenue1 EBITDA INR 8,368 Crore INR 6,608 Crore INR 2,235 Crore H1 FY27 15% YoY 13% YoY 26% YoY Mr. Rajeev Juneja – Vice Chairman & Managing Director  Revenue grew ~17% YoY with EBITDA margins improving by 210 bps to 27.1%  Strong domestic business1 growth of 15.9% led by 1.2x volume outperformance to IPM, further supported by:  Mid-teen growth in Mankind Domestic with 1.1x Chronic outperformance2, led by growth of 19% in Cardiac and 16% in Anti-diabetes  Acute outperformance of 1.1x, led by 19% growth in Gastro, 26% in VMN  Steady double digit growth in BSV domestic specialty business  International business grew 33%, while OTC witnessed muted growth in Q2  Our disciplined execution and strengthening business fundamentals resulted in strong performance. Our recent acquisition of Armed Cell Therapeutics, marks strategic entry into Next-Generation CAR-T therapies, strengthening R&D capabilities for future growth. 1.Domestic business excluding Consumer Healthcare || 2. Ex-Tirzepatide Press Release Q2 FY27 Performance Summary  Revenue from Operations at INR 4,338 Cr, up by 17.3%YoY o Domestic revenue at INR 3,657 Cr, up 14.8%, Exports at INR 681 Cr, up 32.7% YoY  EBITDA margin of 27.1%, up by 210 bps YoY and PAT margin of 16.5%, up 240 bps YoY  Diluted EPS1 of INR 17.2, up 38.9% YoY (FV Re.1) H1 FY27 Performance Summary  Revenue from Operations at INR 8,368 Cr, up by 15.1%YoY o Domestic revenue at INR 7,082 Cr, up 12.7%, Exports at INR 1,286 Cr, up 31.0% YoY  EBITDA margin of 26.7%, up by 230 bps YoY and PAT margin of 15.4%, up 210 bps YoY  Diluted EPS1 of INR 30.9, up 34.6% YoY (FV Re.1) 1. Diluted EPS not annualised Domestic Business1  Domestic revenue (ex CH)2 increased 15.9% YoY driven by strong double digit growth in both Mankind and BSV specialty business  Secondary sales growth of 15.7% vs 14.2% IPM3 in Q2FY27 indicating a 1.1x outperformance to IPM led by:  1.1x outperformance in chronic3 growth supported by 18.7% in Cardiac and 15.8 % in Anti-diabetes  1.1x outperformance in acute driven by Gastro ( 1.3x ), VMN 1.4x); Anti-infectives also recovering QoQ (5.4% in Q2FY27 vs 3.6% in Q1FY27)  Strong growth in key focused brands:  Acute brands like Pantakind (31%), Dydroboon (19%), Cefakind CV (18%), Nurokind LC (18%) in Q2FY27  Chronic brands like Pangraf (60%), Placida (28%), Telmikind AM (16%), Glizid M (15%)  Healthy growth in BSVs key brands - Humog (51%), Lonopin (45 %), Anti D (37 %) and ASVS (45%)  Brands with sales above Rs 50 crore increased to 63 in MAT Sep’26 from 54 in FY26, while brands with sales over Rs 100 crore rose to 26 from 22  Consistently maintained #1 rank over last 9 years with prescription share of 15.2% and prescriber penetration of 84.4% in MAT Aug’26 1.As per IQVIA Sep-2026 // 2.Denotes reported number// 3. Ex-Tirzepatide Consumer Healthcare Business1  Revenue growth impacted by slower offtake in category for the industry and some regional impact in East and South  Despite softer growth, we gained market share in key Brands – Manforce, and Preganews  MT & E-Com share increased to 18% in Q2FY27 as compared to 12% in Q2FY26 supported by 55% growth  Healthy growth in secondary sales for Preganews and Ova news of 14% and 10% YoY respectively in Q2 FY27 1 As per IQVIA / IQVIA Retail Sep-2026 Press Release Exports  International revenue increased by 33% in Q2FY27 driven by strong growth in both Mankind and BSV International  Mankind has launched 1 new product in Q2FY27 taking the total launched products to 50 in US Consolidated Profit & Loss Account Particulars (In INR Crore) Q2 FY27 Q2 FY26 YoY% Q1 FY27 QoQ% Revenue from Operations 4,338 3,697 17.3% 4,031 7.6% Gross Margins % 72.2% 71.3% 90 bps 72.8% (60 bps) EBITDA 1,175 924 27.2% 1,060 10.8% EBITDA Margin % 27.1% 25.0% 210 bps 26.3% 80 bps PAT 716 520 37.7% 574 24.7% PAT Margin % 16.5% 14.1% 240 bps 14.2% 230 bps Particulars (In INR Crore) H1 FY27 H1 FY26 YoY% Revenue from Operations 8,368 7,268 15.1% Gross Margins % 72.5% 70.9% 160 bps EBITDA 2,235 1,774 26.0% EBITDA Margin % 26.7% 24.4% 230 bps PAT 1,290 965 33.7% PAT Margin % 15.4% 13.3% 210 bps Segmental Revenue Break Up Particulars (In INR Crore) Q2 FY27 Q2 FY26 YoY% Q1 FY27 QoQ% Domestic 3,657 3,184 14.8% 3,426 6.7%  Domestic (Ex-CH) 3,428 2,958 15.9% 3,180 7.8%  Consumer Healthcare 229 226 1.2% 246 (7.0%) Exports 681 513 32.7% 605 12.6% Total 4,338 3,697 17.3% 4,031 7.6% Particulars (In INR Crore) H1 FY27 H1 FY26 YoY% Domestic 7,082 6,285 12.7%  Domestic (Ex-CH) 6,608 5,822 13.5%  Consumer Healthcare 475 463 2.6% Exports 1,286 982 31.0% Total 8,368 7,268 15.1% Press Release Earning Concall Details Date 26th October, 2026 Time 05:00 pm – 06:00 pm IST Zoom Link Click here About Mankind Pharma Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women’s health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists. For more information, visit www.mankindpharma.com Safe Harbour Statement The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “Would”, “wi [Showing first 8,000 characters — download PDF for full document]